Remove 2014 Remove Clinical Trials Remove Treatment
article thumbnail

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

Cannabis Law Report

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol. .

article thumbnail

Press Release: Global Wellness Signs Definitive Agreement with Cannvalate Australia

Cannabis Law Report

This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% 2014; 7: 115-124. billion in 2030.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Missouri Republican,Michael Davis, proposes adding access to LSD, MDMA, peyote, and psilocybin as treatment options

Cannabis Law Report

Right-to-try aims to allow patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial to access certain unapproved treatments. Missouri has had its own version of right-to-try since 2014.

article thumbnail

Santé Cannabis and Spectrum Therapeutics Launch Transformative Medical Cannabis Training Program for Québec Healthcare Professionals

Puff Puff Post

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108
article thumbnail

U.S. Funding Focuses on Marijuana’s Harms, Not Benefits

CannaMD

research on marijuana harms – such as cannabis withdrawal, treatments for substance abuse and use/exposure during pregnancy or infancy – received 20 times more funding than research on cannabis therapeutics. While some funds are being used to study cannabis medical treatments, the majority of funding is still used to research harms.

DEA 105
article thumbnail

Global Legal Cannabis Markets Analysis 2021-2028 by Sources (Marijuana, Hemp), End-use (Recreational, Medical), Derivatives (CBD, THC) – ResearchAndMarkets.com

Cannabis Law Report

Medical cannabis is used for the treatment of various chronic conditions, such as Parkinson’s disease, Alzheimer’s disease, arthritis, cancer, depression, anxiety, epilepsy, and other neurological conditions. Thus, a wide application scope has led to an increased product demand for the treatment of various chronic conditions.

article thumbnail

Press Release: MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

Cannabis Law Report

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need.

Therapy 52